Recombinant Gliadin Peptides

Gliadin peptides derived from Triticum aestivum (wheat) are the main immunotoxic antigens in celiac disease. They are a substrates for tissue transglutaminase, which specifically deamidates glutamine residues within these peptides, and therefore strongly increases their immunogenicity (Dørum S. et al., J. Proteome Res. 2009; 8:1748-55).

We offer a set of fusion proteins that carry the different native and deamidated peptide sequences that facilitate the analysis of antibodies found in celiac disease related samples. See also section: Celiac Disease Products

gliadin peptides and DGP variants

Art. No.
G051 26mer gliadin peptide
(26mer-gamma gliadin peptide (aa 59-84) fused to carrier protein)
250 µg
370 €
G052 33mer gliadin peptide
(33mer-alpha gliadin peptide (aa 57-89) fused to carrier protein)
250 µg
370 €
G053 26mer DGP
(26mer-deamidated gamma gliadin peptide (aa 59-84) fused to carrier protein)
250 µg
370 €
G054 33mer DGP
(33mer-deamidated alpha gliadin peptide (aa 57-89) fused to carrier protein)
250 µg
370 €
G055 Carrier protein control
(Control for G051, G052, G053 and G054)
250 µg
370 €
G056 DGP and Gliadin peptides (Set No 1)
(G051, G052, G053, G054 and G055, 100 µg each)
1 Set
740 €


  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.


  • Zedira publication: Microbial Transglutaminase Used in Bread Preparation at Standard Bakery Concentrations Does Not Increase Immunodetectable Amounts of Deamidated Gliadin
  • Pressemitteilung: Dr. Falk Pharma und Zedira geben den Abschluss der Phase 1b-Studie für ZED1227 zur Zöliakie-Therapie bekannt und planen Start der Wirksamkeitsstudie
  • Press release: Dr. Falk Pharma and Zedira announce completion of phase 1b clinical trial of ZED1227 for the treatment of celiac disease and move on to proof of concept study
  • Press Release: Dr. Falk Pharma GmbH and Zedira enter a phase 1b clinical trial for a celiac disease drug
  • Zedira publication: Microbial transglutaminase has a lower deamidation preference than human tissue transglutaminase on a celiac disease relevant wheat gliadin T-cell epitope
  • Press release: Additional subsidy funding for clinical development of a celiac disease drug
  • Pressemitteilung: Zusätzliche Fördermittel für die klinische Entwicklung eines Zöliakie-Medikamentes
  • Press Release: Cooperation between Zedira and Cardiff University - Transglutaminase 6 is the focus of new research into ataxia
  • Press Release: Dr. Falk Pharma and Zedira enter phase I clinical trials for a celiac disease drug
  • Press release: Zedira receives further funding to develop Factor XIIIa-blockers for safe anticoagulation




    13.11.2017 - 16.11.2017
    Düsseldorf, Germany

  • Gordon Research Conference on: Transglutaminases in Human Disease Processes

    16.06.2018 - 17.06.2018
    Les Diablerets, Switzerland